SequelSEC

Sarepta Therapeutics, Inc. SRPT

Pharmaceutical Preparations · CIK 0000873303 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.97B
Fiscal year ended 2026-06-30
Operating income
-$143.25M
Fiscal year ended 2026-06-30
Free cash flow
$81.85M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.67BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$15.91Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin98.8%95th
SBC / revenue5.6%22th
Current ratio2.32x31th
Operating margin-31.8%67th
CapEx / revenue4.6%65th
FCF margin-14.0%64th
Net margin-32.5%63th
Revenue YoY growth15.6%63th
Long-term debt / equity0.73x62th

Sarepta Therapeutics, Inc. (SRPT) reported revenue of $1.97B and net income of -$136.72M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Sarepta Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Sarepta Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.97B
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$143.25M
Net income-$136.72M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$130.92M
Income tax expense$5.80M
Diluted EPS$-1.60
Selling, general & administrative$436.74M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Sarepta Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$571.15M
Total assets$3.19B
Current assets$2.22B
Total liabilities$1.66B
Current liabilities$502.91M
Total equity incl. NCI$1.53B
Temporary (mezzanine) equityUnavailable
Inventory$904.27M
Accounts receivable$376.82M
GoodwillUnavailable
Long-term debt$847.62M
Accounts payable$50.98M

Cash flow

Sarepta Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$111.01M
Capital expenditures$29.16M
Investing cash flow$100.84M
Financing cash flow-$156.76M
Net change in cash$55.10M
Stock-based compensation$98.81M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$44.71M

Derived

Sarepta Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$81.85M
Gross marginUnavailable
Operating margin-7.3%
FCF margin4.1%
SBC / revenue5.0%
Current ratio4.42x
Revenue YoY growth-20.4%
Net margin-6.9%
R&D / revenueUnavailable
CapEx / revenue1.5%
Long-term debt / equity0.55x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SRPT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.